According to other publications, our work identified lower seroconversion rates in CLL patients than in healthy subjects, reflecting the malignancy of the CD5+ B cells that causes deficient humoral immune response in this population (9, 23, 24). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.